(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 September 2015 (11.09.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/134399 A1

(51) International Patent Classification:
A61K 31/4523 (2006.01)

(21) International Application Number:
PCT/US2015/018335

(22) International Filing Date:
2 March 2015 (02.03.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/947,398 3 March 2014 (03.03.2014) US

(71) Applicant: **EISAI R&D MANAGEMENT CO., LTD.** [JP/JP]; 6-10, Koishikawa 4-chome, Tokyo, 112-8088 (JP).

(72) Inventor; and
(71) Applicant *(for US only)*: **LITTLEFIELD, Bruce, A.** [US/US]; 4 Twin Brooks Circle, Andover, MA 01810 (US).

(72) Inventors: **FUNAHASHI, Yasuhiro**; 175 Blossom Street, Unit 905, Boston, MA 02114 (US). **UENAKA, Toshimitsu**; 890 S. Matlack Street, Apt. 333, West Chester, PA 19382 (US).

(74) Agent: **MICHAUD, Susan, M.**; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: USE OF ERIBULIN AND MTOR INHIBITORS AS COMBINATION THERAPY FOR THE TREATMENT OF CANCER

Figure 1



(57) Abstract: Methods for treating cancer (e.g., breast cancer, lung cancer, pancreatic cancer, primitive neuroectodermal tumors, lung cancer, ovaria cancer, endometrial cancer, pharyngeal cancer, esophageal cancer, and sarcoma) in a subject (such as an human patient) in need thereof by administering eribulin (e.g., eribulin mesylate, i.e., E7389, Halaven) in combination with one or more mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus, ridaforolimus, and temsirolimus), and kits therefor are provided.

WO 2015/134399 A1

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*